NASDAQ:RNAZ

Transcode Therapeutics Stock Insider Trading

etoro logo Buy RNAZ
*Your capital is at risk
$4.86
-0.145 (-2.90%)
At Close: Jun 23, 2026

TransCode Therapeutics Stock Insider Power

Based on the 82 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 8.16M and sold 0 RNAZ shares in the last 82 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 82 transactions)
0
Buy 8.16M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Dec 19, 2025
Buy
Common Stock
J-Other
Stover Jack E
Director 0
Value: $0
Oct 06, 2025
Buy
Common Stock
J-Other
Czerepak Elizabeth
Director 0
Value: $0
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Fitzgerald Thomas A
Interim CEO, CFO
CEO / President 650 000
Value: $780.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Calais Philippe
Director
Director 70 000
Value: $84.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Manting Erik
Director
Director 70 000
Value: $84.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Manting Erik
Director
Director 70 000
Value: $84.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Calais Philippe
Director
Director 70 000
Value: $84.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Fitzgerald Thomas A
Interim CEO, CFO
CEO / President 650 000
Value: $780.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Marquet Magda
Director
Director 70 000
Value: $84.0K
Jun 14, 2024
Buy
Stock Option (right to buy)
A-Award
Marquet Magda
Director
Director 70 000
Value: $84.0K
Sep 28, 2023
Buy
Common Stock
P-Purchase
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 49 350
Value: $25.2K
Sep 28, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 98 000
Value: $50.0K
Sep 28, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 98 000
Value: $50.0K
Sep 28, 2023
Buy
Common Stock
P-Purchase
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 49 350
Value: $25.2K
Jun 21, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 12 000
Value: $31.8K
Jun 21, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 12 000
Value: $31.8K
Jun 20, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 6 607
Value: $16.8K
Jun 20, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 6 607
Value: $16.8K
Jun 09, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 19 000
Value: $52.4K
Jun 09, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 19 000
Value: $52.4K
Jun 09, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 19 000
Value: $52.4K
Jun 09, 2023
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 19 000
Value: $52.4K
May 19, 2023
Buy
Stock Option (right to buy)
A-Award
Manting Erik
Director
Director 45 000
Value: $12.8K
May 19, 2023
Buy
Stock Option (right to buy)
A-Award
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 300 000
Value: $85.0K
May 19, 2023
Buy
Stock Option (right to buy)
A-Award
Marquet Magda
Director
Director 45 000
Value: $12.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT TRANSCODE THERAPEUTICS, INC.
TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
20.46% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
OSW
$24.00
17.08% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE